GSK Reports Q2 2026 Results, Driven by Specialty Growth
UKPulse Money Desk
GSK's second-quarter 2026 results show a beat, primarily attributed to growth in its specialty products, alongside plans for over 20 Phase 3 trial starts.
- GSK's Q2 2026 results exceeded expectations.
- Specialty growth was a key driver for GSK's performance.
- GSK plans to initiate more than 20 Phase 3 trials.
GSK has announced its second-quarter 2026 results, indicating that the company's performance surpassed expectations. This positive outcome was largely propelled by growth within its specialty product portfolio.
The pharmaceutical giant also revealed plans to commence over 20 new Phase 3 clinical trials.